- Home
- CSQ vs NAMS Comparison
CSQ vs NAMS Comparison
Compare CSQ & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CSQ | NAMS |
|---|---|---|
| Founded | 2003 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | 100 |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.5B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CSQ | NAMS |
|---|---|---|
| Price | $16.46 | $29.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $46.75 |
| AVG Volume (30 Days) | 317.1K | ★ 836.5K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 7.53% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ N/A |
| Revenue This Year | N/A | $25.64 |
| Revenue Next Year | N/A | $530.85 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.11 | $14.06 |
| 52 Week High | $19.83 | $42.00 |
Technical Indicators
Market Signals| Indicator | CSQ | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 21.93 | 42.50 |
| Support Level | N/A | $23.48 |
| Resistance Level | $19.52 | $31.72 |
| Average True Range (ATR) | 0.36 | 1.65 |
| MACD | -0.11 | 0.11 |
| Stochastic Oscillator | 2.17 | 24.90 |
Price Performance
Historical ComparisonAbout CSQ Calamos Strategic Total Return
Calamos Strategic Total Return Fund is a diversified, closed-end management investment company. The fund's objective is to provide total return through a combination of capital appreciation and current income. Its investment portfolio comprises equities, convertible securities, and high-yield corporate bonds.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.